A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Company Our mission is to detect cancer early, when it can be cured. We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw. Galleri has detected some of the most aggressive cancers in early stages including, among others, endometrial, esophageal, gastrointestinal, head and neck, liver, pancreatic, and rectal cancers.
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 0 | - | - | - |
| Net Income | -408M | -408M | -2.0B | -5.4B |
| EPS | $-11.11 | $-11.11 | $-63.54 | $-173.89 |
| Free Cash Flow | -300M | -300M | -582M | -584M |
| ROIC | -18.6% | -16.1% | -81.0% | -148.1% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.02 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -562M | -562M | -2.2B | -5.4B |
| Operating Margin | 0.0% | - | - | - |
| ROE | -15.8% | -16.1% | -81.0% | -148.1% |
| Shares Outstanding | 37M | 37M | 32M | 31M |
| Metric | 2023 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 330M | 322M | 196M | 196M |
| SG&A | 174M | 214M | 159M | 159M |
| EBIT | -5.4B | -2.2B | -562M | -562M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -5.4B | -2.0B | -408M | -408M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 889M | 889M | 889M |
| Returns on Capital | ||||
| ROIC | -148.1% | -81.0% | -16.1% | -18.6% |
| ROE | -148.1% | -81.0% | -16.1% | -15.8% |
| ROA | -137.9% | -67.9% | -13.8% | -14.0% |
| Cash Flow | ||||
| Op. Cash Flow | -561M | -577M | -299M | -299M |
| Free Cash Flow | -584M | -582M | -300M | -300M |
| Owner Earnings | -792M | -821M | -514M | -514M |
| CapEx | 23M | 5.2M | 909K | 909K |
| Maint. CapEx | 155M | 158M | 156M | 156M |
| Growth CapEx | 0 | 0 | 0 | 0 |
| D&A | 155M | 158M | 156M | 156M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 76M | 86M | 58M | 58M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -110M | -360M | -445M | -195M |
| Cash & Equiv. | 97M | 214M | 250M | 250M |
| Long-Term Debt | N/A | N/A | N/A | 55M |
| Debt/Equity | 0.02 | 0.03 | 0.02 | 0.02 |
| Interest Coverage | N/A | N/A | N/A | N/A |
| Equity | 3.6B | 2.5B | 2.6B | 2.6B |
| Total Assets | 3.9B | 3.0B | 2.9B | 2.9B |
| Total Liabilities | 268M | 480M | 344M | 344M |
| Intangibles | 2.7B | 2.0B | 1.9B | 1.9B |
| Retained Earnings | -7.8B | -9.8B | -10.2B | -10.2B |
| Working Capital | N/A | 743M | 874M | 874M |
| Current Assets | N/A | 820M | 954M | 954M |
| Current Liabilities | 164M | 77M | 80M | 80M |
| Per Share Data | ||||
| EPS | -173.89 | -63.54 | -11.11 | -11.11 |
| Owner EPS | -25.50 | -25.74 | -13.97 | -13.97 |
| Book Value | 117.43 | 78.47 | 70.14 | 70.14 |
| Cash Flow/Share | -18.08 | -18.09 | -8.14 | -6.86 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 31.0M | 31.9M | 36.8M | 36.8M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -4.3 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.2 | N/A | 0.7 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -93.1% | N/A | -17.0% |
| Market Cap | N/A | 625M | 0 | 1.8B |
| Avg. Price | N/A | 15.72 | 0.00 | 48.04 |
| Year-End Price | N/A | 19.60 | 0.00 | 48.04 |
GRAIL, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
GRAIL, Inc. (GRAL) has a 5-year average return on invested capital (ROIC) of -81.7%. This is below average and may indicate limited pricing power.
GRAIL, Inc. (GRAL) has a market capitalization of $1.8B. It is classified as a small-cap stock.
GRAIL, Inc. (GRAL) does not currently pay a regular dividend.
GRAIL, Inc. (GRAL) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
GRAIL, Inc. (GRAL) generated $-300 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
GRAIL, Inc. (GRAL) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
GRAIL, Inc. (GRAL) reported earnings per share (EPS) of $-11.11 in its most recent fiscal year.
GRAIL, Inc. (GRAL) has a return on equity (ROE) of -16.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for GRAIL, Inc. (GRAL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GRAIL, Inc. (GRAL) has a book value per share of $70.14, based on its most recent annual SEC filing.